|
Quelle:
British Medical Journal
Verschiedene kleinere wissenschaftliche Untersuchungen
erbrachten in der Vergangenheit Hinweise darauf, dass die Hyposensibilisierung
bei Heuschnupfen
(aufgrund einer Pollen-
und Gräserallergie)
dann besonders gut anschlägt, wenn die Patienten zusätzlich das
Enzym Beta-Glukoronidase erhalten.
Jetzt zeigte eine im British Medical Journal veröffentlichte
größere Studie, dass diese Therapie-Variante gegenüber der Standardtherapie
keinerlei Vorteile hat.
BMJ
2003;327:251-254 (2 August)
Enzyme potentiated desensitisation in treatment of seasonal allergic
rhinitis: double blind randomised controlled study
Michael J Radcliffe, visiting clinical
research fellow1, George T Lewith, senior clinical research fellow2,
Richard G Turner, associate specialist in allergy3, Philip Prescott,
professor of statistics4, Martin K Church, professor of immunopharmacology1,
Stephen T Holgate, MRC clinical professor of immunopharmacology1
1 School of Medicine, Infection Inflammation and Repair Research
Division, University of Southampton, Southampton General Hospital,
Southampton SO16 6YD, 2 School of Medicine, Community Clinical
Sciences Research Division, University of Southampton, Royal South
Hants Hospital, Southampton SO14 0YG, 3 North Hampshire Hospital,
Basingstoke RG24 9NA, 4 Faculty of Mathematical Studies, University
of Southampton, Southampton SO17 1BJ
Correspondence to: M J Radcliffe michael@radcliffe.net
Objective To assess the
efficacy of enzyme potentiated desensitisation in the treatment
of severe summer hay fever poorly controlled by pharmacotherapy.
Design Double blind randomised
placebo controlled parallel group study.
Setting Hospital in Hampshire.
Participants 183 participants
aged between 18 and 64 with a history of severe summer hay fever
for at least two years; all were skin prick test positive to timothy
grass pollen. 90 randomised to active treatment; 93 randomised
to placebo.
Interventions Active treatment:
two injections of enzyme potentiated desensitisation, given between
eight and 11 weeks apart, each comprising 200 Fishman units of
{beta} glucuronidase, 50
pg 1,3-cyclohexanediol, 50 ng protamine sulphate, and a mixed
inhaled allergen extract (pollen mixes for trees, grasses, and
weeds; allergenic fungal spores; cat and dog danders; dust and
storage mites) in a total volume of 0.05 ml of buffered saline.
Placebo: two injections of 0.05 ml buffered saline solution.
Main outcome measures Proportion
of problem-free days; global rhinoconjunctivitis quality of life
scores assessed weekly during pollen season.
Results The active treatment
group and the placebo group did not differ in the proportion of
problem-free days, quality of life scores, symptom severity scores,
change in quantitative skin prick provocation threshold, or change
in conjunctival provocation threshold. No clinically significant
adverse reactions occurred.
Conclusions Enzyme potentiated
desensitisation showed no treatment effect in this study.
Volltext
|
